Arguing that oversight should protect patients without slowing innovation, the American Hospital Association (AHA) has urged the US Food and Drug Administration (FDA) to adopt a flexible, risk-based approach to regulating generative AI-enabled (GenAI) medical devices.
In comments submitted October 19, the AHA responded to the FDA’s discussion paper on